Objective: The objective of this discussion paper is to illuminate the importance of early identification and treatment of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). SJS/TEN may occur as quickly as 4 days, more commonly 4 to 8 weeks after starting a new medication and early identification is essential.
Methods: A review of literature revealed there is a lack of diagnostic awareness related to the clinical presentation and diverse populations at risk for this devastating syndrome.
Results: A Boolean search was conducted, and six quantitative and qualitative research articles were discovered that indicate a knowledge disparity between "rash" versus SJS/TEN. Research indicates evidence-based best clinical practices for nurses and health care practitioners for assessment of risks, clinical presentation, and treatment.
Conclusions: Prompt diagnosis and discontinuation of the suspected medication will reduce potential life-threatening sequelae.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10783903241252810 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiotherapy-Induced Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis in an Adolescent Girl With Diffuse Glioma of the Pons.
Pediatr Dermatol
December 2024
Dermatology, KK Women's and Children's Hospital, Singapore.
Radiotherapy is a rare cause of Stevens-Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN), especially in the pediatric age group. Most of the reported cases were concomitantly started on anti-epileptic drugs. Herein, we present a case of radiotherapy induced SJS/TEN in an adolescent girl in the absence of anti-epileptic drug use.
View Article and Find Full Text PDFCutaneous Adverse Drug Reactions to Antiseizure Medications.
J Epilepsy Res
December 2024
Department of Dermatology, National Institute of Medical Science and Nutrition Salvador Zubiran, Tlalpan, México.
Discontinuation of antiseizure medications (ASMs), primarily prompted by adverse effects, presents a formidable challenge in the management of epilepsy, and impacting up to 25% of patients. This article thoroughly explores the clinical spectrum of cutaneous adverse drug reactions (cADRs) associated with commonly prescribed ASMs. Ranging from mild maculopapular rashes to life-threatening conditions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the diverse manifestations are meticulously detailed.
View Article and Find Full Text PDFClinical cues for distinguishing bullous fixed drug eruption from Stevens-Johnson syndrome: A case report.
SAGE Open Med Case Rep
December 2024
Department of Dermatology, KCU-GME Consortium/Advanced Dermatology and Cosmetic Surgery, Orlando, FL, USA.
This case report discusses two clinical encounters of a 62-year-old Hispanic woman initially hospitalized with suspected Stevens-Johnson syndrome, later correctly diagnosed with bullous fixed drug eruption during an outpatient visit for a similar eruption. The first encounter involved an extensive evaluation and an 11-day hospital stay, while the second was managed successfully as an outpatient with oral prednisone. This report highlights the importance of differentiating bullous fixed drug eruption from Stevens-Johnson syndrome/toxic epidermal necrolysis and emphasizes the need for a collaborative approach between Primary Care Providers and Dermatology to ensure optimal patient care.
View Article and Find Full Text PDFStevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms are severe cutaneous adverse reactions to drugs that are generally considered distinct entities. In addition to identifying the offending medication, distinguishing between these diagnoses is important, as they have differing treatment regimens and prognoses. Distinction between severe cutaneous adverse reactions, particularly in the early stages of disease, can be difficult, and overlapping conditions have been reported in the literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!